Patient-Controlled Epidural Analgesia After Uterine Artery Embolization
Primary Purpose
Uterine Artery Embolization for Uterine Leiomyomata
Status
Unknown status
Phase
Not Applicable
Locations
Saudi Arabia
Study Type
Interventional
Intervention
Patient-controlled epidural analgesia
Continuous epidural analgesia
Sponsored by
About this trial
This is an interventional treatment trial for Uterine Artery Embolization for Uterine Leiomyomata focused on measuring uterine artery embolization, epidural , patient-controlled analgesia
Eligibility Criteria
Inclusion Criteria:
- Routine elective uterine artery embolization
- uterine leiomyomata
- Epidural anesthesia
Exclusion Criteria:
- Cardiac disorder
- Pulmonary disorder
- Renal disorder
- Hepatic disorder
- Neuropsychiatric disorder
- Bleeding disorder
- Severe anatomical abnormalities of the vertebral column
- Contraindications to epidural analgesia
- Preoperative pain score > 70 mm
- Drug abuse
- Daily intake of analgesics
- Language or mental disorders
Sites / Locations
- King Fahd Hospital of Dammam UniversityRecruiting
- King Fahd Hospital of the UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Patient-controlled epidural analgesia
Continuous epidural analgesia
Arm Description
Patient-controlled epidural analgesia
Continuous epidural analgesia
Outcomes
Primary Outcome Measures
Cumulative consumption of bupivacaine-fentanyl
The cumulative consumption of bupivacaine-fentanyl for 24 hours after uterine artery embolization (UAE) will be recorded
Secondary Outcome Measures
Quality of analgesia
The patients will be asked to rate their experienced pain using the postoperative pain visual analogue scale (VAS) from 0 to 100 mm with 0 representing no pain and 100 representing the worst imaginable pain, for both parietal and visceral pain during rest and upon coughing
Time for first request for rescue analgesia
The time for first request for rescue analgesia (i.e. visual analog scale (VAS) ≥ 50)
Number of supplementary top-up doses required
number of supplementary top-up doses required
Cumulated amounts of local anesthetic consumption
Cumulated amounts of local anesthetic and tramadol consumption for 24-hours after UAE
Overall patient satisfaction
using 100-mm visual analog scale (VAS) (0 very unsatisfied and 100 very satisfied)
Uterine leiomyomata
number and size of uterine leiomyomata
Full Information
NCT ID
NCT02236585
First Posted
September 8, 2014
Last Updated
May 22, 2018
Sponsor
Imam Abdulrahman Bin Faisal University
1. Study Identification
Unique Protocol Identification Number
NCT02236585
Brief Title
Patient-Controlled Epidural Analgesia After Uterine Artery Embolization
Official Title
Does Patient-Controlled Epidural Bupivacaine-Fentanyl Offer Advantages Over Continuous Epidural Infusion After Uterine Arteries Embolization? A Controlled Prospective Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Unknown status
Study Start Date
January 2015 (Actual)
Primary Completion Date
May 2019 (Anticipated)
Study Completion Date
June 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Imam Abdulrahman Bin Faisal University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Uterine artery embolization (UAE) is commonly used to treat symptomatic uterine leiomyomata through induction of infarction and subsequent hyaline degeneration. This could be followed with variable severity of pain that lasts for several days after the procedure secondary to the resulted global uterine ischemia and fibroid infarction. Pain after UAE has been described as moderate to severe cramping increasing over the first 2 hours after UAE to reach plateaus for 5 to 8 hours before it rapidly decreases to a much lower level.1 The severity of pain after UAE seems unrelated to the uterine or fibroid size which makes the severity of pain is unpredictable.1
Pain management after UAE most often consists of a combination of a non-steroidal anti-inflammatory drugs, acetaminophen and an opioid. However severe pain following embolization of the uterine arteries may require large doses of parenteral opioids for relief with added unwanted effects.2
Additionally, patients received morphine intravenous patient-controlled analgesia (IV-PCA) after UAE needed considerable amounts of morphine (median [range] 24 mg [0-86 mg]) during the first 24 h after embolization.3 The addition of ketamine to IV-PCA failed to reduce morphine consumption for the first 24 hours after UAE. 2
Nowadays, the use of lumbar epidural anesthesia has been standardized as the anesthetic choice for uterine artery embolization as it improves patients satisfaction and reduces the severity of post-procedural pain.
Although some investigators suggest an epidural analgesia for pain control after UAE,4 the use of continuous lumbar epidural infusion of ropivacaine does not improve quality of pain management after UAE.5
Thus in an observational study included few patients, the investigators demonstrated considerable postoperative analgesia lasted for 24 hours after UAE with the combined use of patient-controlled thoracic epidural analgesia (PCEA) and rectal diclofenac.6 However, the catheterization of thoracic epidural space in such low-risk patients has many logistic issues.
Up to the best of our knowledge, there is no available comparative randomized clinical trial compares the use of continuous and patient-controlled lumbar epidural analgesia after UAE.
Detailed Description
The investigators hypothesize that the use of a patient-controlled lumbar epidural analgesia (PCEA) will reduce pain scores and improve patient's satisfaction after uterine artery embolization.
The present study is aiming to compare the efficacy of PCEA and continuous epidural infusion of bupivacaine 0.125% with fentanyl 2 µg/ml on the quality of postoperative analgesia after UAE. Furthermore, the investigators aim to study the correlations between the severity of pain after UAE and the number and size of uterine leiomyomata.
Following obtaining of the Local Ethics Committee approval and informed patient consent, sixty patients, aged 18years or older, undergoing routine elective UAE embolization for uterine leiomyomata under epidural anesthesia will be included in this prospective, randomized, controlled, double-blind, comparative study.
On the morning before embolization, the patients will be instructed in the use of the PCA pump and a VAS. The patients will be asked to rate their experienced pain using the VAS from 0 to 100 mm with 0 representing no pain and 100 representing the worst imaginable pain.
Prior to the procedure an 18 to 20 G intravenous access will be established. Patient monitors includes electrocardiograph, non-invasive blood pressure, peripheral oxygen saturation, and respiratory rate. All patients will be premedicated with iv midazolam 0.03 mg/kg.
A lumbar epidural catheter (22-G, B. Braun, Germany) will be placed in L2-4 position using loss of resistance to air and saline on the morning of the procedure. Aspiration and injection of a 3-mL test dose with 2% lidocaine will be used to exclude accidental intravascular or subarachnoid catheter position.
Anesthesia technique will be standardized for all women. A loading epidural dose of 20 ml of 0.25% bupivacaine with 2 μg/ml of fentanyl will be administered in divided 5 ml top-up doses. Epidural catheterization and anesthesia will be done by the attending anesthesiologists who will not be involved in the postoperative assessment of the patient and who is unaware of the patient's group.
Femoral artery will be cannulated with a 2.0 mm sheath of the embolization catheters and UAE will be performed by the same expert interventional radiologist with use of 355-500 μm polyvinyl alcohol particles (Boston Scientific and Cordis, Natick, MA, USA) suspended in 10 ml of iodixanol 270 mg I/ml (Visipaque; Nycomed Amersham, London, UK) mixed with 20 ml of isotonic saline. Embolization will be continued until cessation of UAE blood flow occurs.
After the completion of the procedure and decannulation of the femoral artery, the patients will be randomly allocated into two groups using computer generated randomization codes included in sealed opaque envelopes
According to our adopted protocol, all patients will receive iv infusion of paracetamol 1 g every 6 hours and lornoxicam 8 mg every 12 hours. if patients reached a VAS of ≥ 70 mm despite achieving the maximum preset hourly infusion rates (i.e. 15 ml/hour and 6 ml/hour in the CEA and PCEA groups, respectively), the protocol allows the attending anesthesiologist, who will not be involved in collection of patient data, to unlock the pump temporarily to administer epidural top-up doses of 5 mL of 0.25% bupivacaine plus 2 μg/ml fentanyl every 10 min as required irrespective of the randomization code. If the top-up doses exceeds 25 ml without pain reduction of ≥ 20 mm, an iv bolus injection of 100 mg tramadol will be given.
At the same time, side effects like as nausea, vomiting, itching, hypotension and bradycardia will be assessed and recorded. Nausea and vomiting will be treated with iv granisetron 1 mg. Troublesome pruritus will be treated with chlorpromazine hydrochloride 25 mg im. The patients will be discharged from the hospital after a one-night stay in the hospital. After discharge, pain will be controlled with oral lornoxiacam and paracetamol-codeine.
Using retrospective data from our centre in women received the standard continuous epidural analgesia, a sample size of minimum 30 patients per group was calculated with a study power of 90% to detect a 20% statistically significant difference in the cumulative consumption of bupivacaine for 24-hours after UAE.
Data will be expressed as mean ± SD and analysed using Student 't' test, Mann-Whitney U test and chi square test where appropriate. Linear regression will be performed to define the correlation between the severity of pain as regarding the VAS and the number and size of uterine leiomyomata. P < 0.05 will be considered statistically significant.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Artery Embolization for Uterine Leiomyomata
Keywords
uterine artery embolization, epidural , patient-controlled analgesia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patient-controlled epidural analgesia
Arm Type
Active Comparator
Arm Description
Patient-controlled epidural analgesia
Arm Title
Continuous epidural analgesia
Arm Type
Placebo Comparator
Arm Description
Continuous epidural analgesia
Intervention Type
Procedure
Intervention Name(s)
Patient-controlled epidural analgesia
Intervention Description
Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
Intervention Type
Procedure
Intervention Name(s)
Continuous epidural analgesia
Intervention Description
Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
Primary Outcome Measure Information:
Title
Cumulative consumption of bupivacaine-fentanyl
Description
The cumulative consumption of bupivacaine-fentanyl for 24 hours after uterine artery embolization (UAE) will be recorded
Time Frame
24 hours after procedure
Secondary Outcome Measure Information:
Title
Quality of analgesia
Description
The patients will be asked to rate their experienced pain using the postoperative pain visual analogue scale (VAS) from 0 to 100 mm with 0 representing no pain and 100 representing the worst imaginable pain, for both parietal and visceral pain during rest and upon coughing
Time Frame
every 2 hours intervals after uterine artery embolization
Title
Time for first request for rescue analgesia
Description
The time for first request for rescue analgesia (i.e. visual analog scale (VAS) ≥ 50)
Time Frame
6 hours after surgery
Title
Number of supplementary top-up doses required
Description
number of supplementary top-up doses required
Time Frame
24 hours after surgery
Title
Cumulated amounts of local anesthetic consumption
Description
Cumulated amounts of local anesthetic and tramadol consumption for 24-hours after UAE
Time Frame
24 hours after procedure
Title
Overall patient satisfaction
Description
using 100-mm visual analog scale (VAS) (0 very unsatisfied and 100 very satisfied)
Time Frame
24 hours after surgery
Title
Uterine leiomyomata
Description
number and size of uterine leiomyomata
Time Frame
24 hours before uterine artery embolization
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Routine elective uterine artery embolization
uterine leiomyomata
Epidural anesthesia
Exclusion Criteria:
Cardiac disorder
Pulmonary disorder
Renal disorder
Hepatic disorder
Neuropsychiatric disorder
Bleeding disorder
Severe anatomical abnormalities of the vertebral column
Contraindications to epidural analgesia
Preoperative pain score > 70 mm
Drug abuse
Daily intake of analgesics
Language or mental disorders
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mohamed R El Tahan, MD
Phone
+966 13 865 1193
Email
mohamedrefaateltahan@yahoo.com
First Name & Middle Initial & Last Name or Official Title & Degree
Abdulmohsin A Al Ghamdi, MD
Phone
+966 50 581 4737
Email
mohsenkfu@hotmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bander F Aldhafery, MD
Organizational Affiliation
Chairman of Radiology Dept
Official's Role
Principal Investigator
Facility Information:
Facility Name
King Fahd Hospital of Dammam University
City
Khobar
State/Province
Eastern
ZIP/Postal Code
31592
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mohamed R El Tahan, MD
Phone
+966138966666
Ext
2022
Email
meltahan@ud.edu.sa
Facility Name
King Fahd Hospital of the University
City
Khobar
State/Province
Eastern
ZIP/Postal Code
31952
Country
Saudi Arabia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Abdulmohsen A Al Ghamdi, MD
Phone
+966 13 8966666
Ext
2021
Email
mohsenkfu@hotmail.com
First Name & Middle Initial & Last Name & Degree
Mohamed R El Tahan, MD
First Name & Middle Initial & Last Name & Degree
Alaa M Khidr, MD
First Name & Middle Initial & Last Name & Degree
Ahmed G Hassieb, M.Sec
First Name & Middle Initial & Last Name & Degree
Ahmed Salah, M.Sec.
12. IPD Sharing Statement
Learn more about this trial
Patient-Controlled Epidural Analgesia After Uterine Artery Embolization
We'll reach out to this number within 24 hrs